Key result
Gene polymorphisms of ACE, ATG, and ATR1 showed no association with the risk for chronic heart failure in a study of 100 individuals with CHD, hypertension, or healthy controls.
Why the study?
Does gene polymorphism of the renin angiotensin system affect the risk for chronic heart failure in patients with coronary heart disease and arterial hypertension?
Observational (n=100)
Does gene polymorphism of the renin angiotensin system affect the risk for chronic heart failure in patients with coronary heart disease and arterial hypertension?
Gene polymorphisms of the renin-angiotensin system (ACE, ATG, ATR1) are not associated with the risk of chronic heart failure in patients with coronary heart disease and arterial hypertension.
No support for RAS polymorphism testing in CHF risk assessment for CHD or hypertension; leaves open larger prospective studies.
The purpose of the Study was to search for an association of the gene polymorphism of angiotensin-converting enzyme (ACE), angiotensinogen (ATG) and type I receptors of angiotensin II with the risk for chronic heart failure in patients with coronary heart disease (CHD) and arterial hypertension (AH). A hundred persons, including 80 patients with CHD, 10 patients with hypertensive disease, and 10 healthy Individuals were examined. There was no association of the ID gene polymorphism of ACE, MT gene polymorphism of ATG, and the AC gene polymorphism of ATR1 with the risk for heart failure in patients with CHD and AH.
No takes yet. Share an insight, caveat, or question.
Dorofeev et al. (2005) conducted an observational in Coronary heart disease and arterial hypertension (n=100). Gene polymorphism of ACE, ATG, and ATR1 was evaluated on Risk for chronic heart failure. Gene polymorphisms of ACE, ATG, and ATR1 showed no association with the risk for chronic heart failure in a study of 100 individuals with CHD, hypertension, or healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: